Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

Colin Baigent, Anthony Keech, Patricia M. Kearney, Lisa Blackwell, Georgina Buck, C Pollicino, Adrienne Kirby, T. Sourjina, R Peto, Ruth Collins, R Simes,

The Lancet

September 28, 2005

10.1016/s0140-6736(05)67394-1

Cited by 6,829

Abstract

Related Papers

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

S. Féasson|The Lancet|2002|7k

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group|New England Journal of Medicine|1998|5.3k

Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial

Jeremiah Stamler, Olga Vaccaro, James D. Neaton et al.|Diabetes Care|1993|4.1k

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Peter Sever, Björn Dahlöf, Neil R Poulter et al.|The Lancet|2003|3.8k

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

Rory Collins, Jane Armitage, Sarah Parish et al.|The Lancet|2003|2.9k